Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Halozyme Therapeutics, Inc. on May 5, 2023. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Of the 135,415,332 shares outstanding, 124,528,163 shares were represented at the meeting. The following proposals were voted upon:
- Proposal 1 (Election of Directors): Three Class I directors were elected for a three-year term.
- Bernadette Connaughton: 109,648,595 votes for.
- Moni Miyashita: 109,948,189 votes for.
- Matthew L. Posard: 95,678,233 votes for (notably higher "Against" votes compared to other candidates).
- Proposal 2 (Say-on-Pay): The advisory vote on executive compensation was approved with 107,628,112 votes for.
- Proposal 3 (Frequency of Say-on-Pay): Stockholders voted to hold annual advisory votes on executive compensation (110,411,006 votes for "One Year").
- Proposal 4 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified with 123,271,829 votes for.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, or contingencies. It strictly reports the outcome of the stockholder vote.
Key Facts for Investor Verification
- Verify the specific reasons for the higher "Against" vote count (16,598,543) for director candidate Matthew L. Posard compared to his peers.
- Confirm the company's commitment to annual executive compensation advisory votes as mandated by the stockholder vote.
- Note that the independent auditor for the 2023 fiscal year remains Ernst & Young LLP.
- Review the definitive proxy statement filed on March 24, 2023, for detailed background on the director nominees and executive compensation.